D Tibbitts

No ORCID on file · 1 paper in corpus
nonrandomized-trial 2022
Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18-45
Advances in integrative medicine ·doi:10.1016/j.aimed.2022.04.003

OBJECTIVES: To evaluate the safety and tolerability of encapsulated Tabebuia avellanedae in generally healthy women aged 18-45 with primary dysmenorrhea. METHODS: A single arm, open-label trial was conducted in which 1050 mg/day of encapsu…